GeneXstem

GeneXstem is a clinical-stage biotechnology company focused on the development of regenerative medicine and cellular therapies. The company's primary focus is on leveraging mesenchymal stem cells (MSCs) to treat inflammatory and infectious diseases, with a notable emphasis on respiratory conditions. Their lead program, Z-Stem, has been investigated for its potential to mitigate the cytokine storm associated with COVID-19 and acute respiratory distress syndrome (ARDS). GeneXstem aims to develop scalable, off-the-shelf cell products that can be easily administered in a clinical setting. Led by experienced scientists in the field of immunotherapy, the company continues to explore the broader applications of its stem cell platform in various therapeutic areas.